Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Lai

Showing results (91-100 of 157) with videos related to

Pageof 16
Sort By:
Nature Communications|May 14, 2020
Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosisPing An, Lin-Lin Wei, Shuangshuang Zhao, et al.
Journal of Gastroenterology and Hepatology|March 23, 2011
Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver diseaseKevin Z Qu, Ke Zhang, Wanlong Ma, et al.
Digestive Diseases and Sciences|October 15, 2015
Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASHCarolina F M G Pimentel, Zhenghui G Jiang, Takeshi Otsubo, et al.
Plos One|April 21, 2015
Quantitative assessment of antibody internalization with novel monoclonal antibodies against Alexa fluorophoresSindy Liao-Chan, Barbara Daine-Matsuoka, Nathan Heald, et al.
JHEP Reports : Innovation in Hepatology|February 11, 2020
Quantitative digital pathology reveals association of cell-specific <i>PNPLA3</i> transcription with NAFLD disease activityBynvant Sandhu, Maria C Perez Matos, Stephanie Tran, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 25, 2017
Serum Activity of Macrophage-Derived Adenosine Deaminase 2 Is Associated With Liver Fibrosis in Nonalcoholic Fatty Liver DiseaseZ Gordon Jiang, Bynvant Sandhu, Linda Feldbrügge, et al.
International Journal of Molecular Sciences|September 9, 2023
Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic SteatohepatitisWaseem Amjad, Irina Shalaurova, Erwin Garcia, et al.
Hepatology (Baltimore, Md.)|April 3, 2021
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 TrialSamer Gawrieh, Mazen Noureddin, Nicole Loo, et al.
Journal of Clinical Gastroenterology|April 1, 2017
Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver DiseaseZhenghui G Jiang, Elliot B Tapper, Misung Kim, et al.
Hepatology Communications|December 18, 2018
A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver DiseaseChristopher J Danford, Margery A Connelly, Irina Shalaurova, et al.
Pageof 16

Showing results (91-100 of 157) with videos related to

Sort By:
Pageof 16
Nature Communications|May 14, 2020
Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosisPing An, Lin-Lin Wei, Shuangshuang Zhao, et al.
Journal of Gastroenterology and Hepatology|March 23, 2011
Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver diseaseKevin Z Qu, Ke Zhang, Wanlong Ma, et al.
Digestive Diseases and Sciences|October 15, 2015
Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASHCarolina F M G Pimentel, Zhenghui G Jiang, Takeshi Otsubo, et al.
Plos One|April 21, 2015
Quantitative assessment of antibody internalization with novel monoclonal antibodies against Alexa fluorophoresSindy Liao-Chan, Barbara Daine-Matsuoka, Nathan Heald, et al.
JHEP Reports : Innovation in Hepatology|February 11, 2020
Quantitative digital pathology reveals association of cell-specific <i>PNPLA3</i> transcription with NAFLD disease activityBynvant Sandhu, Maria C Perez Matos, Stephanie Tran, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 25, 2017
Serum Activity of Macrophage-Derived Adenosine Deaminase 2 Is Associated With Liver Fibrosis in Nonalcoholic Fatty Liver DiseaseZ Gordon Jiang, Bynvant Sandhu, Linda Feldbrügge, et al.
International Journal of Molecular Sciences|September 9, 2023
Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic SteatohepatitisWaseem Amjad, Irina Shalaurova, Erwin Garcia, et al.
Hepatology (Baltimore, Md.)|April 3, 2021
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 TrialSamer Gawrieh, Mazen Noureddin, Nicole Loo, et al.
Journal of Clinical Gastroenterology|April 1, 2017
Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver DiseaseZhenghui G Jiang, Elliot B Tapper, Misung Kim, et al.
Hepatology Communications|December 18, 2018
A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver DiseaseChristopher J Danford, Margery A Connelly, Irina Shalaurova, et al.
Pageof 16